Lv51
1530 积分 2022-06-20 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2小时前
已完结
Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
1个月前
已关闭
Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trial
1个月前
已完结
Mechanisms of Resistance to Antibody-Drug Conjugates
1个月前
已完结
Mechanisms of Resistance to Antibody-Drug Conjugates
1个月前
已关闭
Mechanisms of Resistance to Antibody–Drug Conjugates
1个月前
已完结
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
2个月前
已完结
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
7个月前
已完结
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
7个月前
已完结
Treatment strategy for EGFR mutated NSCLC
8个月前
已完结
皖公网安备34019202002308
